Good managers set the tone for the whole team, encouraging positive behavior from everyone around them. In the November 5 Nature, scientists introduce a subtype of microglia that appears to do just ...

Hypertension heightens the risk of Alzheimer’s disease, but exactly how is not understood. In a bioRxiv preprint posted September 19, scientists led by Costantino Iadecola at Weill Cornell Medical ...

This knock-in (KI) mouse model was generated by introducing a D427V point mutation into exon 10 of the mouse Gba1 (glucosidase, beta, acid 1) gene, which corresponds to the human D409V mutation (The ...

These mice have a targeted deletion in the mouse gene β-site APP cleaving enzyme 1 (BACE1). Homozygous mice are viable, fertile, normal in size, and do not display any gross physical or behavioral ...

This APP transgenic overexpresses mutant human APP under the control of the Thy-1.2 promoter, driving neuronal expression. The transgene carries two mutations associated with familial Alzheimer’s ...

901 E. Willeta Street Phoenix, AZ85006 United States Visit Website Contact: Eric Reiman, M.D. Phone: 602-839-6999 Fax: 602-239-6253 E-mail: eric.reiman@bannerhealth ...

In a watershed moment for the field, the U.S. Food and Drug Administration today approved the first Alzheimer’s treatment that tackles the underlying disease pathology. Biogen and Eisai’s anti-amyloid ...

In Phase 3, HMTM failed to meet co-primary endpoints. Subgroup analysis of an open-label extension suggests benefit in people with MCI. In that subgroup, half as many people transitioned to AD. HMTM ...

In a draft decision, the CMS proposed covering Aduhelm only in clinical trials. Most Alzheimer’s researchers support the proposal. Some challenged its practicality. The manufacturers of the other anti ...

The top-line results last September from Eisai’s Phase 3 trial of the anti-amyloid antibody lecanemab galvanized the field, but scientists said they needed to see the data before passing judgement.

Buoyed by data crediting amyloid removal with ever-so-slightly slowed cognitive decline, many scientists are now optimistic about the prospects for anti-amyloid immunotherapy. Four “-mabs”—of the ...

Earlier this year, a high-profile Science paper caused a stir with its claim that the brain has a fourth, previously unrecognized, meningeal membrane. Dubbed SLYM and containing Prox1+ cells, this ...